{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T19:36:01Z","timestamp":1771529761903,"version":"3.50.1"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2013,7,16]],"date-time":"2013-07-16T00:00:00Z","timestamp":1373932800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Br J Cancer"],"published-print":{"date-parts":[[2013,8]]},"DOI":"10.1038\/bjc.2013.368","type":"journal-article","created":{"date-parts":[[2013,7,16]],"date-time":"2013-07-16T20:00:15Z","timestamp":1374004815000},"page":"552-558","source":"Crossref","is-referenced-by-count":84,"title":["Phase II study of pemetrexed and carboplatin plus bevacizumab as first-line therapy in malignant pleural mesothelioma"],"prefix":"10.1038","volume":"109","author":[{"given":"G L","family":"Ceresoli","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P A","family":"Zucali","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M","family":"Mencoboni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M","family":"Botta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F","family":"Grossi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D","family":"Cortinovis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N","family":"Zilembo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C","family":"Ripa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M","family":"Tiseo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A G","family":"Favaretto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H","family":"Soto-Parra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F","family":"De Vincenzo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A","family":"Bruzzone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E","family":"Lorenzi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L","family":"Gianoncelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B","family":"Ercoli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L","family":"Giordano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A","family":"Santoro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2013,7,16]]},"reference":[{"key":"BFbjc2013368_CR1","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1007\/s11912-012-0238-8","volume":"14","author":"T Abu-Hejleh","year":"2012","unstructured":"Abu-Hejleh T, Mezhir JJ, Goodheart JJ, Halfdanarson TR (2012) Incidence and management of gastrointestinal perforation from bevacizumab in advanced cancers. Curr Oncol Rep 14: 277\u2013284.","journal-title":"Curr Oncol Rep"},{"issue":"suppl","key":"BFbjc2013368_CR2","doi-asserted-by":"publisher","first-page":"7006","DOI":"10.1200\/jco.2011.29.15_suppl.7006","volume":"29","author":"P Baas","year":"2011","unstructured":"Baas P, Buikhuisen W, Dalesio O, Vincent A, Pavlakis N, Van Klaveren R, Schramel F, Custers F, Schouwink H, Burgers SA (2011) A multicenter, randomized phase III maintenance study of thalidomide (arm A) versus observation (arm B) in patients with malignant pleural mesothelioma (MPM) after induction chemotherapy. J Clin Oncol 29 (suppl): abstr 7006.","journal-title":"J Clin Oncol"},{"key":"BFbjc2013368_CR3","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1093\/annonc\/mdh059","volume":"15","author":"MJ Byrne","year":"2004","unstructured":"Byrne MJ, Nowak AK (2004) Modified RECIST criteria for assessment of response in malignant pleural mesothelioma. Ann Oncol 15: 257\u2013260.","journal-title":"Ann Oncol"},{"key":"BFbjc2013368_CR4","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1038\/nature10144","volume":"473","author":"P Carmeliet","year":"2011","unstructured":"Carmeliet P, Jain RK (2011) Molecular mechanisms and clinical application of angiogenesis. Nature 473: 298\u2013307.","journal-title":"Nature"},{"key":"BFbjc2013368_CR5","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1093\/annonc\/mdm501","volume":"19","author":"B Castagneto","year":"2008","unstructured":"Castagneto B, Botta M, Aitini E, Spigno F, Degiovanni D, Alabiso O, Serra M, Muzio A, Carbone R, Buosi R, Galbusera V, Piccolini E, Giaretto L, Rebella R, Mencoboni M (2008) Phase II study of pemetrexed in combination with carboplatin in patients with malignant pleural mesothelioma (MPM). Ann Oncol 19: 370\u2013373.","journal-title":"Ann Oncol"},{"key":"BFbjc2013368_CR6","doi-asserted-by":"publisher","first-page":"1443","DOI":"10.1200\/JCO.2005.04.3190","volume":"24","author":"GL Ceresoli","year":"2006","unstructured":"Ceresoli GL, Zucali PA, Favaretto AG, Grossi F, Bidoli P, Del Conte G, Ceribelli A, Bearz A, Morenghi E, Cavina R, Marangolo M, Soto-Parra HJ, Santoro A (2006) Phase II study of pemetrexed plus carboplatin in malignant pleural mesothelioma. J Clin Oncol 24: 1443\u20131448.","journal-title":"J Clin Oncol"},{"key":"BFbjc2013368_CR7","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.ctrv.2009.09.003","volume":"36","author":"GL Ceresoli","year":"2010","unstructured":"Ceresoli GL, Zucali PA, Gianoncelli L, Lorenzi E, Santoro A (2010) Second-line treatment for malignant pleural mesothelioma. Cancer Treat Rev 36: 24\u201332.","journal-title":"Cancer Treat Rev"},{"key":"BFbjc2013368_CR8","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1517\/13543784.2012.681641","volume":"21","author":"GL Ceresoli","year":"2012","unstructured":"Ceresoli GL, Zucali PA (2012) Anti-angiogenic therapies for malignant pleural mesothelioma. Expert Opin Investig Drugs 21: 833\u2013844.","journal-title":"Expert Opin Investig Drugs"},{"key":"BFbjc2013368_CR9","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/j.2517-6161.1972.tb00899.x","volume":"34","author":"DR Cox","year":"1972","unstructured":"Cox DR (1972) Regression models and life tables. J R Stat Soc B 34: 187\u2013220.","journal-title":"J R Stat Soc B"},{"key":"BFbjc2013368_CR10","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1200\/JCO.1998.16.1.145","volume":"16","author":"D Curran","year":"1998","unstructured":"Curran D, Sahmoud T, Therasse P, van Meerbeeck J, Postmus PE, Giaccone G (1998) Prognostic factors in patients with pleural mesothelioma: the European Organization for Research and Treatment of Cancer experience. J Clin Oncol 16: 145\u2013152.","journal-title":"J Clin Oncol"},{"key":"BFbjc2013368_CR11","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1016\/j.lungcan.2012.05.111","volume":"77","author":"J Dowell","year":"2012","unstructured":"Dowell J, Dunphy FR, Taub RN, Gerber DE, Ngov L, Yan J, Xie Y, Kindler HL (2012) A multicenter phase II study of pemetrexed, cisplatin and bevacizumab in patients with advanced malignant mesothelioma. Lung Cancer 77: 567\u2013571.","journal-title":"Lung Cancer"},{"key":"BFbjc2013368_CR12","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1016\/S1470-2045(09)70112-3","volume":"10","author":"S Hapani","year":"2009","unstructured":"Hapani S, Chu D, Wu S (2009) Risk of gastrointestinal perforation in patients with cancer treated with bevacizumab: a meta-analysis. Lancet Oncol 10: 559\u2013568.","journal-title":"Lancet Oncol"},{"key":"BFbjc2013368_CR13","doi-asserted-by":"publisher","first-page":"3533","DOI":"10.1200\/JCO.2002.10.073","volume":"20","author":"A Hughes","year":"2002","unstructured":"Hughes A, Calvert P, Azzabi A, Plummer R, Johnson R, Rusthoven J, Griffin M, Fishwick K, Boddy AV, Verrill M, Calvert H (2002) Phase I clinical and pharmacokinetic study of pemetrexed and carboplatin in patients with malignant pleural mesothelioma. J Clin Oncol 20: 3533\u20133544.","journal-title":"J Clin Oncol"},{"key":"BFbjc2013368_CR14","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1002\/cncr.23617","volume":"113","author":"DM Jackman","year":"2008","unstructured":"Jackman DM, Kindler HL, Yeap BY, Fidias P, Salgia R, Lucca J, Morse LK, Ostler PA, Johnson BE, J\u00e4nne PA (2008) Erlotinib plus bevacizumab in previously treated patients with malignant pleural mesothelioma. Cancer 113: 808\u2013814.","journal-title":"Cancer"},{"key":"BFbjc2013368_CR15","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1038\/nrclinonc.2009.63","volume":"6","author":"RK Jain","year":"2009","unstructured":"Jain RK, Duda DG, Willett CG, Sahani DV, Zhu AX, Loeffler JS, Batchelor TT, Sorensen AG (2009) Biomarkers of response and resistance to antiangiogenic therapy. Nat Rev Clin Oncol 6: 327\u2013338.","journal-title":"Nat Rev Clin Oncol"},{"key":"BFbjc2013368_CR16","doi-asserted-by":"publisher","first-page":"1172","DOI":"10.1016\/S1470-2045(10)70232-1","volume":"11","author":"AM Jubb","year":"2010","unstructured":"Jubb AM, Harris AL (2010) Biomarkers to predict the clinical efficacy of bevacizumab in cancer. Lancet Oncol 11: 1172\u20131183.","journal-title":"Lancet Oncol"},{"key":"BFbjc2013368_CR17","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1080\/01621459.1958.10501452","volume":"53","author":"EL Kaplan","year":"1958","unstructured":"Kaplan EL, Meier P (1958) Nonparametric estimation of incomplete observations. J Am Stat Assoc 53: 457\u2013481.","journal-title":"J Am Stat Assoc"},{"key":"BFbjc2013368_CR18","doi-asserted-by":"publisher","first-page":"2537","DOI":"10.1002\/sim.4780142304","volume":"14","author":"T Karrison","year":"1995","unstructured":"Karrison T (1995) Comparison of median survival times with adjustment for covariates. Stat Med 14: 2537\u20132553.","journal-title":"Stat Med"},{"key":"BFbjc2013368_CR19","doi-asserted-by":"publisher","first-page":"2509","DOI":"10.1200\/JCO.2011.41.5869","volume":"30","author":"HL Kindler","year":"2012","unstructured":"Kindler HL, Karrison TTG, Gandara DR, Lu C, Krug LM, Stevenson JP, J\u00e4nne PA, Quinn DI, Koczywas MN, Brahmer JR, Albain KS, Taber DA, Armato SG 3rd, Vogelzang NJ, Chen HX, Stadler WM, Vokes EE (2012) Multicenter, double-blind, placebo-controlled, randomized phase II trial of gemcitabine\/cisplatin plus bevacizumab or placebo in patients with malignant mesothelioma. J Clin Oncol 30: 2509\u20132515.","journal-title":"J Clin Oncol"},{"key":"BFbjc2013368_CR20","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1002\/(SICI)1096-9896(199909)189:1<72::AID-PATH401>3.0.CO;2-0","volume":"189","author":"S Kumar-Singh","year":"1999","unstructured":"Kumar-Singh S, Weyler J, Martin MJ, Vermeulen PB, Van Marck E (1999) Angiogenic cytokines in mesothelioma: a study of VEGF, FGF-1 and -2, and TGF beta expression. J Pathol 189: 72\u201378.","journal-title":"J Pathol"},{"key":"BFbjc2013368_CR21","doi-asserted-by":"publisher","first-page":"5918","DOI":"10.1158\/1078-0432.CCR-07-0501","volume":"13","author":"Q Li","year":"2007","unstructured":"Li Q, Yano S, Ogino H, Wang W, Uehara H, Nishioka Y, Sone S (2007) The therapeutic efficacy of anti-vascular endothelial growth factor antibody, bevacizumab, and pemetrexed against orthotopically implanted human pleural mesothelioma cells in severe combined immunodeficient mice. Clin Cancer Res 13: 5918\u20135925.","journal-title":"Clin Cancer Res"},{"key":"BFbjc2013368_CR22","doi-asserted-by":"publisher","first-page":"3284","DOI":"10.1200\/JCO.2008.20.8181","volume":"27","author":"JD Patel","year":"2009","unstructured":"Patel JD, Hensing TA, Rademaker A, Hart EM, Blum MG, Milton DT, Bonomi PD (2009) Phase II study of pemetrexed and carboplatin plus bevacizumab with maintenance pemetrexed and bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer. J Clin Oncol 27: 3284\u20133289.","journal-title":"J Clin Oncol"},{"issue":"60","key":"BFbjc2013368_CR23","first-page":"65","volume":"26","author":"SS Ramalingam","year":"2008","unstructured":"Ramalingam SS, Dahlberg SE, Langer CJ, Gray R, Belani CP, Brahmer JR, Sandler AB, Schiller JH, Johnson DH (2008) Outcomes for elderly, advanced-stage non small-cell lung cancer patients treated with bevacizumab in combination with carboplatin and paclitaxel: analysis of Eastern Cooperative Oncology Group Trial 4599. J Clin Oncol 26 (60): 65.","journal-title":"J Clin Oncol"},{"key":"BFbjc2013368_CR24","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1001\/jama.2011.51","volume":"305","author":"V Ranpura","year":"2011","unstructured":"Ranpura V, Hapani S, Wu S (2011) Treatment-related mortality with bevacizumab in cancer patients. JAMA 305: 487\u2013494.","journal-title":"JAMA"},{"key":"BFbjc2013368_CR25","doi-asserted-by":"publisher","first-page":"1860","DOI":"10.1245\/s10434-006-9337-9","volume":"14","author":"MW Saif","year":"2007","unstructured":"Saif MW, Elfiki A, Salem RR (2007) Gastrointestinal perforation due to bevacizumab in colorectal cancer. Ann Surg Oncol 14: 1860\u20131869.","journal-title":"Ann Surg Oncol"},{"key":"BFbjc2013368_CR26","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1097\/JTO.0b013e31817c73d6","volume":"3","author":"A Santoro","year":"2008","unstructured":"Santoro A, O\u2019Brien ME, Stahel RA, Nackaerts K, Baas P, Karthaus M, Eberhardt W, Paz-Ares L, Sundstrom S, Liu Y, Ripoche V, Blatter J, Visseren-Grul CM, Manegold C (2008) Pemetrexed plus cisplatin or pemetrexed plus carboplatin for chemonaive patients with malignant pleural mesothelioma: results of the International Expanded Access Program. J Thorac Oncol 3: 756\u2013763.","journal-title":"J Thorac Oncol"},{"key":"BFbjc2013368_CR27","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1016\/0197-2456(96)00075-X","volume":"17","author":"M Schemper","year":"1996","unstructured":"Schemper M, Smith TL (1996) A note on quantifying follow-up in studies of failure time. Control Clin Trials 17: 343\u2013346.","journal-title":"Control Clin Trials"},{"key":"BFbjc2013368_CR28","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.ccr.2008.08.001","volume":"14","author":"Y Shaked","year":"2008","unstructured":"Shaked Y, Henke E, Roodhart JML, Mancuso P, Langerberg MH, Colleoni M, Daenen LG, Man S, Xu P, Emmenegger U, Tang T, Zhu Z, Witte L, Strieter RM, Bertolini F, Voest EE, Benezra R, Kerbel RS (2008) Rapid chemotherapy-induced acute endothelial progenitor cell mobilization: implications for antiangiogenic drugs as chemosensitizing agents. Cancer Cell 14: 263\u2013273.","journal-title":"Cancer Cell"},{"key":"BFbjc2013368_CR29","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1183\/09031936.00063109","volume":"35","author":"A Scherpereel","year":"2010","unstructured":"Scherpereel A, Astoul P, Baas P, Berghmans T, Clayson H, de Vuyst P, Dienemann H, Galateau-Salle F, Hennequin C, Hillerdal G, Le P\u00e9choux C, Mutti L, Pairon JC, Stahel R, van Houtte P, van Meerbeeck J, Waller D, Weder W (2010) Guidelines of the European Respiratory Society and the European Society of Thoracic Surgeons for the management of malignant pleural mesothelioma. Eur Resp J 35: 479\u2013495.","journal-title":"Eur Resp J"},{"key":"BFbjc2013368_CR30","doi-asserted-by":"publisher","first-page":"5580","DOI":"10.1002\/cncr.27576","volume":"118","author":"JP Stevenson","year":"2012","unstructured":"Stevenson JP, Langer CJ, Somer RA, Evans TL, Rajagopalan K, Krieger K, Jacobs-Small M, Dyanick N, Milcarek B, Coakley S, Walker S, Eaby-Sandy B, Hageboutros A (2012) Phase 2 trial of maintenance bevacizumab alone after bevacizumab plus pemetrexed and carboplatin in advanced, nonsquamous nonsmall cell lung cancer. Cancer 118: 5580\u20135587.","journal-title":"Cancer"},{"key":"BFbjc2013368_CR31","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1002\/path.824","volume":"193","author":"L Strizzi","year":"2001","unstructured":"Strizzi L, Catalano A, Vianale G, Orecchia S, Casalini A, Tassi G, Puntoni R, Mutti L, Procopio A (2001) Vascular endothelial growth factor is an autocrine growth factor in human malignant mesothelioma. J Pathol 193: 468\u2013475.","journal-title":"J Pathol"},{"key":"BFbjc2013368_CR32","doi-asserted-by":"publisher","first-page":"2081","DOI":"10.1200\/JCO.2008.19.8523","volume":"27","author":"AS Tsao","year":"2009","unstructured":"Tsao AS, Wistuba I, Roth JA, Kindler HL (2009) Malignant pleural mesothelioma. J Clin Oncol 27: 2081\u20132090.","journal-title":"J Clin Oncol"},{"key":"BFbjc2013368_CR33","doi-asserted-by":"publisher","first-page":"6881","DOI":"10.1200\/JCO.20005.14.589","volume":"23","author":"JP Van Meerbeeck","year":"2005","unstructured":"Van Meerbeeck JP, Gaafar R, Manegold C, Van Klaveren RJ, Van Marck EA, Vincent M, Legrand C, Bottomley A, Debruyne C, Giaccone G (2005) Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an intergroup study of the European Organization for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada. J Clin Oncol 23: 6881\u20136889.","journal-title":"J Clin Oncol"},{"key":"BFbjc2013368_CR34","doi-asserted-by":"publisher","first-page":"2636","DOI":"10.1200\/JCO.2003.11.136","volume":"21","author":"NJ Vogelzang","year":"2003","unstructured":"Vogelzang NJ, Rusthoven JJ, Symanowski J, Denham C, Kaukel E, Ruffie P, Gatzmeier U, Boyer M, Emri S, Manegold C, Niyikiza C, Paoletti P (2003) Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 21: 2636\u20132644.","journal-title":"J Clin Oncol"},{"key":"BFbjc2013368_CR35","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1097\/JTO.0b013e3181d2f008","volume":"5","author":"A Yasumitsu","year":"2010","unstructured":"Yasumitsu A, Tabata C, Tabata R, Hirayama N, Murakami A, Yamada S, Terada T, Iida S, Tamura K, Fukuoka K, Kuribayashi K, Nakano T (2010) Clinical significance of serum vascular endothelial growth factor in malignant pleural mesothelioma. J Thorac Oncol 5: 479\u2013483.","journal-title":"J Thorac Oncol"},{"key":"BFbjc2013368_CR36","doi-asserted-by":"crossref","unstructured":"Zalcman G, Mazieres J, Scherpereel A, Margery J, Moro-Sibilot D, Parienti JJ, Gounant V, Riviere A, Monnet I, Molinier O, Lena H, Friard S, Duhamel JP, Audigier-Valette C, Robinet G, Creveuil C, Ligeza-Poisson C, Morin F (2012) IFCT-GFPC-0701 MAPS trial, a multicenter randomized phase II-III trial of pemetrexed-cisplatin with or without bevacizumab in patients with malignant pleural mesothelioma. J Clin Oncol 30 (): (suppl): abstr TPS7112).","DOI":"10.1200\/jco.2012.30.15_suppl.tps7112"},{"key":"BFbjc2013368_CR37","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1016\/j.ctrv.2011.01.001","volume":"37","author":"PA Zucali","year":"2011","unstructured":"Zucali PA, Ceresoli GL, De Vincenzo F, Simonelli M, Lorenzi E, Gianoncelli L, Santoro A (2011) Advances in the biology of malignant pleural mesothelioma. Cancer Treat Rev 37: 543\u2013558.","journal-title":"Cancer Treat Rev"}],"container-title":["British Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/bjc2013368.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/bjc2013368","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/bjc2013368.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,14]],"date-time":"2024-05-14T20:16:24Z","timestamp":1715717784000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/bjc2013368"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,7,16]]},"references-count":37,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2013,8]]}},"alternative-id":["BFbjc2013368"],"URL":"https:\/\/doi.org\/10.1038\/bjc.2013.368","relation":{},"ISSN":["0007-0920","1532-1827"],"issn-type":[{"value":"0007-0920","type":"print"},{"value":"1532-1827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,7,16]]}}}